In recent years, the technology and methods widely available for mass spectrometry (MS)-based proteomics have increased in power and potential, allowing the study of protein-level processes occurring in biological systems. Although these methods remain an active area of research, established techniques are already helping answer biological questions. Here, this recent evolution of MS-based proteomics and its applications are reviewed, including standard methods for protein and peptide separation, biochemical fractionation, quantitation, targeted MS approaches such as selected reaction monitoring, data analysis and bioinformatics. Recent research in many of these areas reveals that proteomics has moved beyond simply cataloguing proteins in biological systems and is finally living up to its initial potential -as an essential tool to aid related disciplines, notably health research. From here, there is great potential for MS-based proteomics to move beyond basic research, into clinical research and diagnostics.
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When, in 2000, the draft of the sequenced human genome was introduced, many new avenues of research for exploring human health became available. One field that experienced an explosion of interest was proteomics, the study of the protein complement of a cell under certain conditions. Although these newly uncovered genome sequences revealed which protein sequences could be expressed, splicing, post-translational modifications (PTMs), tertiary structure, enzymatic activity, formation of complexes and ligand interactions combine to produce a much richer protein environment than what is simply coded for, and it is these intricate and complex processes that dictate how biological functions occur. Proteomic research is the attempt to understand all that is occurring in this complex environment, with the aim of elucidating protein-level processes involved in biological activity.
The first tentative steps towards mass spectrometry (MS)-based proteomics started in the late 1980s, well before the human genome was sequenced, when the development of softionisation techniques such as electrospray ionisation (ESI) (Ref. 1) and matrix-assisted laser desorption/ionisation (MALDI) (Ref. 2 ) allowed MS analysis of intact biological macromolecules for the first time. These technologies, together with the fact that peptides produced through the digestion of proteins with highly specific proteases are characteristic of their parent protein, permitted protein identification by comparison of MS data with known sequences, in silico. Progress in this field generated a great deal of fervour, and researchers began to develop new techniques, as well as incorporate established techniques, to aid proteome analysis by MS. The years that followed saw gargantuan leaps in the capabilities of MS and related technologies.
So why all the excitement? It is mainly due to the ability of MS to obtain specific and sensitive information about a complex sample quickly, over a wide dynamic range. Given that the genome of a given species codes for many thousands of protein products [∼20 500 for humans (National Human Genome Research Institute, http://www.genome.gov)], which cover many orders of magnitude in abundance (ten in the case of plasma) (Ref. 3) , twodimensional (2D) gel electrophoresis was initially the only technology capable of sensitive and reproducible visualisation of the proteome. MS, combined with a host of affiliated technologies, provided the first opportunity to go beyond gel-based visualisation, enabling discovery and identification of the components of a proteome on a large scale, to a depth that immunoprecipitations and 2D gels could not provide. These proteome-wide discovery experiments were the basis of the initial thrust in MS-based proteomics, inspiring a rapid rate of creation and improvement of new techniques and instrumentation in an attempt to dig deeper into the proteome, with more certainty, less sample and less time. This focus on instrumentation brought together different combinations of mass analyser and ion source, and fostered the utilisation of the strengths of different mass analysers in hybrid instruments (Ref. 4) . Research and development continue to produce and improve mass spectrometers to this day (Ref. 5) . Although these technique and technology improvements have resulted in the greatly increased utility and robustness of MS-based proteomics, what does this mean for tangible benefits to human health research? Essentially, it means that proteomics has moved beyond simply asking the 'what' of a biological question, and now can routinely and robustly study the 'when, where, how and how much'. Current popular techniques and experiment types employed in MS-based proteomics that are now being utilised in biomedical research are discussed in this review (Fig. 1 ).
Protein and peptide separation techniques
The field of MS-based proteomics can be categorised into two broad approaches. The increasingly popular 'top-down' proteomic approach focuses on the analysis of intact proteins, whereas the more widely used 'bottom-up' proteomic approach focuses on the analysis of peptides following proteolytic digestion of proteins, and is the main topic of this review (Ref. 6 ). Because 'bottom-up' proteomic approaches require digestion of proteins into peptides prior to their analysis by MS, preanalytical sample processing plays an important role and should be carefully considered when designing and conducting these types of experiments. By far the most popular method to prepare a proteomic sample is enzymatic digestion using trypsin, which is very well suited to downstream analysis by the most common MS and tandem MS (MS/MS) techniques. However, information regarding PTMs or protein isoforms could be missed, and it is often worth considering other proteolytic enzymes or applying a panel of enzymes (Ref. 7) . The digestion of proteins into peptides prior to MS analysis greatly increases the complexity of samples, and the separation of these complex samples into manageable, reproducible fractions is an issue that proteomics has battled with since its inception.
Owing to several factors, including competitive ionisation of coeluting species, dynamic range limitations (the ability to analyse a weak signal in the presence of a strong signal), duty cycle constraints (how many things can be analysed per unit of time) and resolving power, it is generally known that the greater the separation before MS sequencing, the better the results Another commonly used method for proteinlevel sample fractionation prior to MS is the 'GeLC' approach. It harnesses the wellestablished ability and available equipment for running gels, by separating a complex sample by molecular weight at the protein level in a single 1D SDS-PAGE gel lane, and using that lane as the first dimension in a multidimensional separation. After staining, the entire lane is excised, cut into bands and each band is treated as a fraction of the same sample. After the proteins in these bands are enzymatically digested, each band's peptide mixture can be analysed on an LC-MS/MS instrument and the results combined. The benefits of gel-based protein-level first-dimension separation are threefold: gels are often a good way of making biological samples compatible with MS analysis (e.g. by removal of detergents), method development is not needed as SDS-PAGE is a well-established technique, and the number of identifications obtained per experiment is currently second to none. In fact, of the aforementioned protein-level separation techniques, the GeLC approach has been found to provide the highest number of confident protein or peptide identifications, although the alternative approach of immobilised pH gradient (IPG)-based IEF has the benefit of slightly higher sample recovery over the GeLC separation (Ref. 17) . A recently developed fractionation method termed GELFrEE (gel-eluted liquid figure. ) Whole-cell lysates can be used for a global proteome analysis, or more in-depth analysis and additional spatial information can be obtained using subcellular fractionation. Alternatively, cells can be lysed and proteins or posttranslation modifications (PTMs) of interest can be isolated by affinity enrichment methods. All methods produce protein mixtures, which can be separated further by exploiting various protein properties such as molecular weight or isoelectric points, and are digested in the next step. Separating the generated peptides is recommended and leads to deeper resolution. Peptides are then analysed by MS (e.g. LC-MS/MS) and in unbiased discovery experiments peptides and the corresponding proteins are identified using databasematching search algorithms, followed by quantitative and bioinformatic evaluation of the data. Alternatively, targeted MS for specific peptides and proteins can be performed using SRM. Quantitative information can be obtained either by label-free methods or by applying a differential isotopic labelling method at one of the stages indicated on the right: metabolic labels such as SILAC and N15 can be introduced at cell level, whereas chemical labelling methods such as iTRAQ, ICPL or ICAT are utilised either at protein or at peptide level. Isotopic labelling can also be introduced during proteolysis, and synthetic standard isotopic peptides can be added to the peptide mixture (AQUA). Abbreviations: AQUA, absolute quantitation; ICAT, isotopecoded affinity tags; ICPL, isotope-coded protein labelling; iTRAQ, isobaric tags for relative and absolute quantitation; LC-MS/MS, liquid chromatography tandem mass spectrometry; MS, mass spectrometry; N15, 15 N isotope; PTM, post-translational modification; SILAC, stable isotope labelling of amino acids in cell culture; SRM, selected reaction monitoring.
fraction entrapment electrophoresis) also separates proteins based on their size using a gel column; however, in contrast to the GeLC method, the proteins are eluted and collected in the liquid phase (Ref. 18 ). The researcher needs to be aware of these performance differences in firstdimension separations when deciding on the priorities for a given experiment.
Peptide separation
The development of powerful techniques and chemistries for separation at the peptide level has led many MS-based workflows to forgo the aforementioned protein-level separations entirely. Many options exist for the firstdimension separation, which have varying degrees of orthogonality: for example, reversedphase chromatography, which resolves issues with solvent compatibility; or strong ion exchange, different forms of which can provide good sample complementarity. One of the most common first-dimension separations for largescale proteomic experiments is peptide-level strong cation exchange (SCX) chromatography. There is no 'best' answer for separation; despite each of the techniques being optimal for particular sample types, they will all provide complementary results.
First-dimension separations can be performed off-line with a fraction collector, although when they are performed in-line with a reversed-phase column as the second dimension prior to MS, in a workflow called multidimensional protein information technology (MudPIT) (Refs 19, 20) , the experiment is capable of significant proteome coverage (approximately 60%) in one -albeit very long -experiment (Ref. 21 ). This type of workflow is described thoroughly in a published protocol (Ref. 22) . Reproducing an experiment of this type also provides 60% of the proteome, with a large number of the peptides sequenced being species that were not sequenced in the first experiment. It is estimated that it would take five MudPIT experiments performed in this way to achieve near-complete sequence coverage, a phenomenon attributed to MS/MS peptide-sampling rates. As with any MS-based analysis of complex samples, the limitations of this method are time and instrument duty cycle -issues that should be considered when designing experiments and choosing which proteomic approach to use. These limitations can be attenuated by conducting biological and technical repeats and maximising separation and fractionation prior to MS analysis. Also, the development of dynamic exclusion lists to avoid run-to-run resequencing of peptides has recently increased the number of extracellular proteins identified in repeat analyses of the human embryonic stem cell secretome by an order of magnitude (Ref. 21) . Expanding the MudPIT workflow to include a third dimension of separation has also been shown to work well (Ref. 23) , and a study of the proteome of the serum of patients with sepsis utilised immunodepletion of abundant serum proteins followed by a 3D peptide-level separation, allowing the identification of lowabundance serum proteins while identifying ten potential serum biomarkers for sepsis (Ref. 24) . Although this type of technique shifts the limitation of the method towards separation time and away from the duty cycle of the instrument, the deployment of fast, ultrahigh-pressure liquid chromatography (UPLC) (Ref. 25 ; http://www. waters.com/waters/nav.htm?locale=en_US&cid= 10136122) in many laboratories is now proving that these methods are more powerful than ever.
Biochemical fractionation methods
The protein-or peptide-separation techniques described above allow in-depth analysis of a complex sample. However, biochemical fractionation procedures, which add an additional dimension of separation, can lead to even deeper resolution as the separation methods described previously can be performed on a less complex sample. This can be especially important in highly complex samples, such as human plasma or serum, which have a high dynamic range spanning at least ten orders of magnitude. These samples contain a small number of highly abundant proteins, whose signals can dominate MS-based analysis. Depletion of these proteins can be highly advantageous in allowing access to lower abundance species, including potential disease biomarkers, and there are many tried and tested depletion strategies available (Refs 26, 27) . For cellular studies, spatial information (e.g. which proteins are found in which organelles or which proteins interact with each other) can be extremely important for understanding a complex system, and can be obtained by applying either subcellular fractionation or affinity enrichment techniques.
Subcellular fractionation
For subcellular analysis, every classical biochemical fractionation procedure, whether it be membrane enrichment, nucleus precipitation or mitochondria preparation, can be used as the first enrichment step, followed by protein/ peptide separation and MS analysis. For example, plasma membrane lipid rafts were enriched to follow the effects of DMSO-induced differentiation of HL-60 cells into neutrophils by LC-MS/MS, and out of 147 identified proteins, 25 were found to be upregulated and 49 were downregulated (Ref. 28) . In a different study, membrane fractionation and the hydrazide method were used to isolate 25 glycoproteins from breast cancer cell lines, which are considered putative cancer biomarkers (Ref. 29) .
Immunoprecipitation
Affinity enrichment of a protein and its interaction partners decreases the complexity of a sample dramatically and provides information about the composition of the interaction network. Classical coimmunoprecipitation, a long-established method to isolate proteins, is the first step performed for this approach, applying either antibodies against endogenous proteins or immunoaffinity tags. Precipitated proteins are isolated afterwards and analysed as described earlier. In contrast to an immunoblot analysis, which requires a hypothesis about interaction partners and focuses on the identification of one protein, MS is an unbiased detection method and allows the discovery of several binding partners at once, including unexpected ones. However, MS is a very sensitive method and therefore stringent wash conditions, several controls and careful interpretation of the results are required to obtain correct information from this type of experiment (Ref. 30) . For example, the interaction network of MYC was studied using the tandem affinity purification (TAP) approach, which allows stringent wash steps and thereby reduces false-positive identifications; 221 putative interaction partners were identified, of which only 17 were known before (Ref. 31).
Another approach was applied for the study of integrin-linked kinase (ILK), where a quantitative MS approach (see below) was used to distinguish between proteins binding to the bait protein or to the tag itself and allowed the identification of several novel ILK-interacting proteins (e.g. α-tubulin) (Ref. 32) . Two complementary affinity purification methods were used to identify over 40 kinases binding to dasatinib, an inhibitor with putative antitumour properties. In a second step, phosphorylated proteins were purified from cancer cells; 23 candidates identified in both pull-downs were analysed in more detail regarding their susceptibility to the inhibitor and several of these kinases were found to be inhibited by dasatinib (Ref. 33 ).
Phosphorylation-enrichment strategies
Enriching for PTMs also simplifies a complex sample, and studying the corresponding proteins can provide detailed information about signalling processes. Furthermore, even though PTMs can be identified by MS, the low stoichiometry of these modifications can lead to them being missed during analysis, a problem that can be overcome by specific affinity enrichment. One of the major modifications taking place during signal transduction is phosphorylation, the study of which -termed phosphoproteomics -has also pioneered technology development. The epidermal growth factor (EGF) signalling pathway has been studied in detail by several groups using slightly different MS approaches and can be seen as a model system for the optimisation of phosphoproteomics (Ref. 37 ). Mann and colleagues have applied many methods, including the application of antiphosphotyrosine antibodies (Ref. 38) , the use of titanium dioxide to enrich phosphopeptides (Ref. 39 ) and the combination of both enrichment approaches, on the way to developing a method termed qPACE, which allows the study of very early signalling events (Ref. 40) . For quantitation, they utilised SILAC. By contrast, White and colleagues used iTRAQ to study EGF receptor signalling using a combinational enrichment approach applying antiphosphotyrosine antibodies and IMAC (Ref. 41) , and extended their methodology with selected reaction monitoring (SRM) experiments (which are explained in detail later in this review), allowing a much higher reproducibility (Ref. 42) . Phosphoproteomics is now used to study other and unknown signalling pathways, as for example the SYK signalling cascade, which was originally described only in haematopoietic cells but has been investigated now in human cancer cells to shed more light on the role of this kinase in cancer formation (Ref. 43) .
With the help of the enrichment techniques described here, MS-based proteomics can achieve high spatial and functional resolution. However, as mentioned throughout this section, a quantitative dimension is also frequently necessary to answer many of the questions currently asked by researchers.
Quantitative approaches
The topic of MS-based quantitation exploded in the mid-2000s (Ref. 44) , and the current state of the art is reviewed thoroughly and engagingly elsewhere (Ref. 45) . Essentially, despite quantitative proteomics still being an active area of research on its own, it is now also available to human health researchers who are interested in studying drug effects, biomarkers of disease and the pathways involved in disease processes.
Isotopic labelling techniques
Mass spectrometers are not inherently quantitative.
Differences in ionisation, transmission and detection efficiency dictate that the intensity of a signal from a particular molecule is a relative measure of its abundance, but not an absolute measure. For this reason, all quantitative proteomics, even 'absolute' quantitation is relative -relative to an internal standard' (Ref. 45) . MS-based proteomic quantitation was therefore not thrust into the mainstream until 1999, when isotope-coded affinity tags (ICATs) were introduced (Ref. 46) . These tags were the first widely available method to quantify the relative concentrations of peptides or proteins in a sample, by way of an isotope-coded chemical modifier. Briefly, each of two samples is treated with either one of a 'light' or 'heavy' chemical reagent that binds specifically to cysteine residues. The light and heavy tags are chemically identical, except for isotopic differences. The two samples are then mixed and digested, and the tagged peptides are enriched using avidin or streptavidin chromatography against the biotin moiety embedded in the tag. On performing MS analysis on these enriched samples, the chemically identical species from the two samples will coelute from a column and ionise with identical efficiency; however, the peptide that is modified with the 'light' form of the reagent will appear at a known lower mass in the spectrum than the 'heavy' tagged equivalent peptide from the other sample. One can then directly compare the peak areas of the two chemically identical coeluting peptides and thereby obtain a relative measure of their abundance. Relative quantitation, performed through isotope-coding methods similar to this, is the best way to obtain information about quantitative differences in protein expression, especially from the complex samples usual in proteomics (Fig. 2) .
One issue with the ICAT method described above, however, is its dependence on the modification of cysteine residues, which account for only 1.42% of the amino acids in a sample (Ref. 47 ). Many peptides, and even whole proteins, do not contain a cysteine, and are therefore unquantifiable by means of ICAT. This problem was resolved in 2004 with the introduction of the isobaric tags for relative and absolute quantitation (iTRAQ) label (Ref. 48) (Applied Biosystems; http://www.appliedbio systems.com). With this tag, initially four, and now up to eight, samples can be compared together, using labels with identical mass shifts. This is achieved through the differential placement of the stable isotopes onto 'balance' and 'reporter' pieces of the tag, which are separated by a labile bond. Each of the different tag 'flavours' adds the same overall mass to a peptide, bound through the balance group to the primary amines on lysine side chains and the N-termini of peptides. On mixing of the samples, unlike ICAT-labelled samples, tagged peptides will appear as one signal in a normal MS scan. Only upon fragmentation does the labile bond holding the iTRAQ modification together dissociate, forming an intense marker ion from the reporter group, each of which will be specific for one of the samples to be compared. This behaviour allows for high specificity (marker ion intensity can only be from the peptide currently being fragmented) and high sensitivity because the isobaric nature of the tag dictates that the intensities of the signals from all samples are additive for initial detection in the MS scan, and subsequent sequencing. This technique has also been successfully used in the tandem mass tag (TMT) strategy from Thermo Scientific (http://www. piercenet.com).
These types of chemical labelling strategies are a good choice when probing the proteome of human cells or tissues that cannot or should not be cultured. Unfortunately, as the combination of the samples to be compared occurs late in this workflow, there is a chance of systematic errors during sample handling (Fig. 2) . Metabolic labelling techniques, in which cells are grown in isotopically labelled media and compared with those grown in normal media, have been shown to be the most accurate proteomic quantitation method mainly due to the ability to combine samples very early in the procedure (e.g. immediately after lysis), thus minimising errors involved with differential sample handling in the subsequent isolation and purification steps (Ref. 38 
Label-free quantitation
Given that the intensity of the signal in a mass spectrometer is innately a proxy of the abundance of the species in the sample, labelfree quantitation approaches have recently entered the mainstream because of their apparent ease, simplicity and cost savings. One of the numerous label-free quantitation approaches is 'spectral counting', in which the MS/MS spectra collected for a given species are counted and compared with those collected for the same species in a different sample. This technique uses the assumption that unbiased, intensity-based precursor ion selection leads to intense ions being selected for sequencing more frequently. The number of MS/MS spectra collected for a given analyte would therefore be a proxy of its intensity, and therefore its abundance. Like all label-free quantitation methods, systematic errors in the analysis, such as signal suppression, detector saturation and differential sample loading, occur. These errors need to be minimised and accounted for by performing many replicates, normalising the data, and statistical validation (Refs 45, 52). Although this approach has been shown to be adequate for quantitation of high-abundance components of a mixture (Ref. 53 ), isotopic labelling techniques, which correct for these figure. ) (a) SILAC incorporates isotopes early in the sample preparation procedure, maximising accuracy and reproducibility, and is generally used only for quantitation of samples from cells that can be cultured. Isotope incorporation into the amino acids themselves means peptides to be compared have different masses; therefore quantification occurs from the MS scan. (b) Chemical isotope-coded tags are applied later in the workflow, but can be applied to any biologically derived sample. Isobaric chemical tags (iTRAQ, TMT) add equivalent masses to the peptides in the sample, but produce specific marker ions upon fragmentation, allowing quantification from the MS/MS scan. Abbreviations: iTRAQ, isobaric tags for relative and absolute quantitation; MS, mass spectrometry; MS/MS, tandem mass spectrometry; SILAC, stable isotope labelling of amino acids in cell culture; TMT, tandem mass tag.
systematic errors and also allow for sample multiplexing, are still the method of choice for quantitative proteomics. The commonly used quantitative proteomic methods, along with their strengths and weaknesses, are shown in Table 1 .
Targeted analysis: selected reaction monitoring
Unlike global proteomic techniques, which operate based on intensity-dependent fragmentation of precursor ions and are biased towards more abundant proteins, SRM (also known as multiple reaction monitoring, MRM) targets predetermined precursor ions for fragmentation (Fig. 3) 
SRM and quantitation
The SRM approach can be used to quantitate proteins. Relative quantitation can be conducted simply by comparing the absolute peak area of the individual samples (label-free quantitation), although it is difficult to obtain precise measurements because of differences in ionisation efficiency, analyte composition and chromatography. SRM experiments can also be combined with many of the standard isotope labels used in quantitative proteomic experiments, including ICAT, SILAC, ICPL and iTRAQ. Additionally, several methods that aid greatly in speeding up the assay development aspect of SRM have emerged, including databases such as MRMAtlas (Ref. 63 ) and a method of crude synthetic peptide library production, which allow the rapid generation of validated SRM assays for whole proteomes (Ref. 56 ). These approaches have been pioneered using the yeast proteome, but the development of databases and resources such as this for clinically relevant tissues could help thrust SRMbased quantitation firmly into the clinical arena.
Applications of SRM
The advantages of SRM experiments have led to an almost exponential increase in the number of studies using this approach in recent years (Ref. 62) , and SRM has now been applied to many diverse biological questions, from the quantitation of the biomarker C-reactive protein (CRP) in the serum of patients with rheumatoid arthritis (Ref. 64 ) to the absolute quantitation of the human liver alcohol dehydrogenase ADH1C1 isoenzyme (Ref. 65 ) and pyruvate kinase M2 (PKM2), a potential endometrial expert reviews http://www.expertreviews.org/ in molecular medicine 
75). SRM-MS has several
advantages over antibody assays for biomarker validation: SRM has exquisite sensitivity, with no crossreactivity and less specificity issues than are often associated with antibody assays; SRM is 'reagent independent'; SRM can be used for any MS-observable ion, making it generally cheaper than antibody assays (Ref. 76); and these assays are quantitative and easily multiplexed. This is a key point, as reality dictates that having a single biomarker for a disease is unlikely; panels of biomarkers are the more likely future of disease diagnostics, and SRM technologies are very well placed to study these. Issues still remain however, particularly regarding assay throughput and precision, which have not been thoroughly tested and currently do not meet the US Food and Drug Administration (FDA) requirements for routine clinical tests (Ref. 75). Another issue is operator familiarity, as these assays are only beginning to enter the mainstream, and it will take time for users to become comfortable with applying these new techniques. However, the hurdles facing the use of SRM in biomarker validation are slowly being overcome, and although antibody assays will still be used for biomarker validation, increasingly we can expect to see the application of SRM assays.
Bioinformatic analysis
With the rapid development of MS-based proteomic technologies, automated analysis of the qualitative and quantitative data resulting from large-scale proteomic studies has become increasingly important and challenging (Ref. 77) . The large number of MS/MS spectra generated in a typical proteomic experiment requires several stages of analysis, including statistical validation of peptide and protein identifications, analysis of any quantitative information and interpretation of the resultant protein information.
Protein identification
Identification of peptides and their corresponding proteins is generally conducted using search algorithms that correlate experimental MS/MS spectra to theoretically derived spectra created from known peptide sequences. There are several different search engines available, which differ in their approaches to identifying peptide sequences. The most common search algorithms include Sequest (Ref. 
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Intensity (cps) Similarly, Mascot Distiller, from Matrix Science, determines quantitation based on the relative intensities of extracted ion chromatograms for precursors (http://www.matrixscience.com). This approach can be used for 'label-free' approaches, or with any chemistry that creates a precursor mass shift, for example 18 O, AQUA, ICAT, ICPL, metabolic labelling and SILAC. ProteinPilot, from Applied Biosystems (http:// www.appliedbiosystems.com), provides protein identification and quantitation of SILAC-and iTRAQ-based labels. For label-free approaches, there are many open-source and commercial software packages available, which are discussed in a recent review (Ref. 86). It is worth noting that for the analysis of quantitative proteomic data, no standard procedure has been developed that is broadly applicable to all experiment types. As is evident, many software tools exist, and the user still needs to understand what the software is doing in order to be able to critically analyse the results.
Analysis of quantitative proteomic data

Data-mining approaches
With the rapid growth in large-scale proteomic experiments comes the generation of longer and longer lists of proteins. However, the sound biological interpretation of these data lags behind (Ref. 77). There are now several analytical strategies and tools available to extract biologically relevant information (e.g. regarding protein-protein interactions, signalling pathways and biological networks) from these large proteomic datasets. These 'data-mining' approaches have the potential to contribute to a deeper understanding of biological systems, but need to be applied and interpreted correctly. One of the most powerful tools available, and often the first tool used to conduct analysis on a large dataset, is Gene Ontology (GO) (Ref. 87). This is a controlled vocabulary that is used to standardise the way in which proteins are described across different species and databases. The consistency in terminology that this ontology provides makes it an invaluable resource for both experimentalists and bioinformaticians. GO annotation of a large MS dataset can be used to determine whether there is any enrichment or depletion for a particular GO category, or can be used to compare two different datasets.
Pathway and network analysis
Another useful approach is pathway analysis, which explores proteomic data in terms of biological pathways, based on known physical and functional interactions between proteins that are present. It is estimated that there are around 300 biochemical pathway analysis tools currently available (Ref. 77), with the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Reactome representing the largest databases. Many of the pathway analysis tools are freely available, but there are also some commercially available tools -for example, Ingenuity Pathways Analysis from Ingenuity Systems, and GeneGo from GeneGo Inc. With so many pathway analysis options to choose from, Pathguide (http://www.pathguide.org), which contains information on about 317 biological pathway tools, is an invaluable resource to help guide users in selecting the most appropriate resource to use (Ref. 88). Pathguide also covers tools that model network and functional interaction information, which takes the data beyond pathway analysis and groups proteins based on participation in larger, multiprotein assemblies. For visualisation of molecular networks, Cytoscape is a useful open-source platform, which also allows integration of genetic and other information (Refs 89, 90).
There are now several meta-databases for interaction information, including STRING (Refs 91, 92), which generates interaction networks by incorporating data from many curated databases, as well as predicted interactions and pathway information. Data can be input to STRING as protein lists, and it has a user-friendly interface. MiMI, from the National Institute for Integrative Biomedical Informatics, merges data from numerous interaction databases as well as other sources and also has a Cytoscape plug-in to allow easy visualisation of networks (Ref. 93). For all interaction databases, which can have high error rates, care needs to be taken when interpreting information and the source of the interaction information should be checked manually if possible.
Meta-data analysis and data integration
One of the key challenges currently facing researchers is the integration of all these available data. There are several tools available for metadata analysis of proteomic data, including the database for annotation, visualisation and integrated discovery (DAVID), from the National Institute of Allergy and Infectious Diseases (NIAID), which provides a comprehensive set of functional annotation tools for investigators to understand the biological meaning behind large lists of genes. Other meta-tools include PANTHER (protein analysis through evolutionary relationships, http://www.pantherdb.org), which was designed to classify proteins (and their genes) in order to facilitate high-throughput analysis, and Babelomics, which is a suite of interconnected tools used to functionally annotate genome-scale experiments. Conceptgen, from the National Institute for Integrative Biomedical Informatics, is a web-based tool designed to explore networks of relationships between biological concepts (Ref. 94). The Global Proteome Machine (http:// www.thegpm.org), a search engine and database for MS/MS data, links the protein identifications directly to annotation resources such as GO and KEGG within the same platform, allowing efficient examination of the GOs and pathways under-or over-represented in a particular dataset.
Discussion: biological and clinical applications
One of the initial goals of proteomics was the collection of inventories of whole proteomes. However, the real strength behind proteomic approaches lies in the ability to compare and quantitate samples. Formerly, 2D gel analysis was one of the only ways to gain quantitative information on a set of proteins, and although there are still many current publications successfully using this approach, alternative techniques such as isotopic labelling are currently supplanting 2D gels as a preferred quantitation method. Many studies applying these approaches have successfully identified biomarkers with clinical potential. For example, a recent study used a combination of murine cancer models and iTRAQ quantitation to discover a novel, putative biomarker for gastric cancer (Ref. 107) (Fig. 4) . The biomarker was then validated in serum from cancer patients. Quantitation is especially important in the study of time-dependent processes, such as the changes that take place during storage of blood before transfusion. The platelet storage lesion has been studied by applying several complementary quantitative proteomic approaches to platelets at days 1 and 7 of storage (Ref. 108) . 2D gel electrophoresis/ differential gel electrophoresis (DIGE), iTRAQ and ICAT were used, resulting in 503 protein changes identified over the course of storage, the majority of which were identified using the iTRAQ method. Despite this, the benefit of expert reviews http://www.expertreviews.org/ in molecular medicine using multiple quantitative proteomic approaches was evident, as less than 16% of the 503 proteins were identified by two or more proteomic approaches and only five proteins were identified by all approaches.
Combining the technologies discussed in this review is a good way of utilising the ). An optimised lysis and digestion method was developed to address this problem, which is performed in one tube. Furthermore, by optimising the parameters of the LC-MS/MS system for the analysis of small amounts of cells it was possible to analyse as few as 500 cells, from which 167 proteins were identified (Ref. 113) . Another problem still faced by the proteomic community is accessibility to low-abundance proteins, particularly in the presence of high-abundance proteins, such as in the analysis of serum. Depletion methods can be used to remove these proteins in order to investigate lower abundance proteins; however, some peptides and proteins bind to these carrier proteins and are discarded through this procedure. As an alternative approach, a differential solubilisation method was developed to enrich for low-abundance proteins in plasma. By analysing these enriched fractions with high-quality MALDI-TOF (time of flight), more than 1500 peptides from a 1 μl serum sample were identified and four new potential colon cancer biomarkers were discovered (Ref. 114) . This approach has the potential to greatly contribute to the discovery of novel low-abundance biomarkers. One aspect that is especially important for the analysis of biomarkers in serum is reproducibility: it has been shown that serum proteins are degraded by endogenous proteases shortly after a blood draw, leading to varying results. However, the addition of protease inhibitors to the blood drawing tubes can counteract this effect and stabilise serum proteins (Ref. 115) .
As outlined in this article, MS-based proteomic approaches are now applied to many diverse aspects of clinical research, some of which are highlighted in Table 3 , and the ultimate hope is for the development of diagnostic and prognostic tools that will benefit human health. As more potential biomarkers move from the discovery phase towards clinical trials, there is the need for accurate statistical and mathematical analysis of the data, in order to better determine key outcomes, for example precision and accuracy, using standardised tests such as positive predictive value (Ref. 116). figure. ) (a) A mouse xenograft model was used to identify putative biomarkers for gastric cancer. Tumours were induced in mice with the human gastric cancer cell line MKN45 and mice were categorised according to tumour burden [low (length, L = 1-2 mm, volume, V = 2-3 mm 3 ); mid (L = 7.5 mm, V = 127-210 mm 3 ); high (L = 15 mm, V = 726-1078 mm 3 )]. Plasma from these mice and a control group was labelled with four different iTRAQ labels and studied by LC-MS/MS. Triplicates were performed to obtain high-quality data. (b) Thirty-one proteins were identified as putative biomarkers, and the presence of one of these proteins, ITIH3, was analysed in serum derived from healthy humans (normal) and gastric cancer patients (cancer) by immunoblotting. ITIH3 levels were found to be elevated significantly (P-value <0.001) in cancer patients. (c) An ROC curve was generated using the data from (b) to estimate the accuracy of ITIH3 detection in gastric cancer detection. Sensitivity was determined to be very high, at 96%, whereas specificity was slightly lower, at 66%. The area under the ROC curve was found to be 0.86 (with 0.5 being a useless and 1.0 a perfect test), which implies that ITIH3 could be a valuable biomarker in early gastric cancer detection. Figure adapted with Tables  Table 1. MS quantitation techniques. Table 2 . Examples of selected reaction monitoring (SRM) resources. Table 3 . Recent examples of clinical applications of proteomics.
